北大医药董事长兼总裁徐晰人被刑拘，股价跳空低开

Core Viewpoint - The recent criminal detention of the chairman and president of Beijing University Pharmaceutical has raised concerns about the company's governance and operational stability, leading to a significant drop in its stock price [1][7]. Company Governance - On October 25, Beijing University Pharmaceutical announced that its chairman and president, Xu Xiren, was temporarily unable to perform his duties due to personal reasons, delegating responsibilities to other executives [1]. - On October 29, the company disclosed that Xu Xiren had been criminally detained and was cooperating with investigations, which has led to uncertainty regarding the company's future [1]. - The company stated that its control structure remains unchanged, and its board operations, financial, and operational management are normal as of the announcement date [1]. Stock Market Reaction - Following the news of Xu Xiren's detention, the company's stock opened lower on October 30, experiencing an intraday drop of 8.59%, closing at 5.74 yuan per share, with a market capitalization of approximately 3.42 billion yuan [1]. Business Overview - Beijing University Pharmaceutical positions itself as an integrated pharmaceutical technology enterprise focusing on the research, production, and sales of chemical drug formulations, with a focus on areas such as anti-infection, analgesics, mental health, and chronic diseases [1]. - The company currently holds 166 drug approvals and 13 first-generic drug approvals [1]. Recent Changes in Control - The company underwent significant management changes in early 2024, with multiple resignations due to personal reasons, including the chairman and president [2][4]. - Xu Xiren was elected as chairman in April 2025 and appointed as president in July 2025 [5]. Financial Performance - In 2024, the company reported revenues of 2.06 billion yuan, a year-on-year decline of 6.10%, while achieving a net profit of 138 million yuan, a significant increase of 211.10% [7]. - The third-quarter report for 2025 indicated revenues of 1.23 billion yuan, a year-on-year decrease of 19.76%, with a net profit of 136 million yuan, reflecting a 4.31% increase [7]. - The company anticipates a potential revenue decrease of approximately 600 million yuan (29.13% of the latest audited revenue) and a net profit decrease of around 40 million yuan (28.99% of the latest audited net profit) due to the termination of a key business partnership [7].